X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Piramal Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA PIRAMAL ENTERPRISES GSK PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 64.5 39.3 164.1% View Chart
P/BV x 10.4 3.3 316.9% View Chart
Dividend Yield % 1.2 0.7 164.1%  

Financials

 GSK PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    GSK PHARMA
Mar-17
PIRAMAL ENTERPRISES
Mar-17
GSK PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs3,8382,095 183.2%   
Low Rs2,6371,025 257.3%   
Sales per share (Unadj.) Rs354.2492.8 71.9%  
Earnings per share (Unadj.) Rs39.872.6 54.8%  
Cash flow per share (Unadj.) Rs42.994.7 45.3%  
Dividends per share (Unadj.) Rs30.0021.00 142.9%  
Dividend yield (eoy) %0.91.3 68.8%  
Book value per share (Unadj.) Rs236.9862.5 27.5%  
Shares outstanding (eoy) m84.70172.56 49.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x9.13.2 288.7%   
Avg P/E ratio x81.421.5 378.7%  
P/CF ratio (eoy) x75.516.5 458.3%  
Price / Book Value ratio x13.71.8 755.4%  
Dividend payout %75.428.9 260.7%   
Avg Mkt Cap Rs m274,216269,194 101.9%   
No. of employees `0004.74.0 117.0%   
Total wages/salary Rs m4,83017,939 26.9%   
Avg. sales/employee Rs Th6,387.021,190.3 30.1%   
Avg. wages/employee Rs Th1,028.34,470.1 23.0%   
Avg. net profit/employee Rs Th717.13,120.0 23.0%   
INCOME DATA
Net Sales Rs m30,00085,037 35.3%  
Other income Rs m7282,338 31.2%   
Total revenues Rs m30,72887,374 35.2%   
Gross profit Rs m4,19034,991 12.0%  
Depreciation Rs m2633,817 6.9%   
Interest Rs m020,310 0.0%   
Profit before tax Rs m4,65513,202 35.3%   
Minority Interest Rs m01,699 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m457-100 -459.3%   
Tax Rs m1,7442,281 76.5%   
Profit after tax Rs m3,36812,520 26.9%  
Gross profit margin %14.041.1 33.9%  
Effective tax rate %37.517.3 216.8%   
Net profit margin %11.214.7 76.2%  
BALANCE SHEET DATA
Current assets Rs m16,74287,590 19.1%   
Current liabilities Rs m7,202185,578 3.9%   
Net working cap to sales %31.8-115.2 -27.6%  
Current ratio x2.30.5 492.5%  
Inventory Days Days5231 166.9%  
Debtors Days Days2148 43.7%  
Net fixed assets Rs m8,635108,523 8.0%   
Share capital Rs m847345 245.4%   
"Free" reserves Rs m19,222148,481 12.9%   
Net worth Rs m20,069148,826 13.5%   
Long term debt Rs m10144,957 0.0%   
Total assets Rs m30,038482,394 6.2%  
Interest coverage xNM1.7-  
Debt to equity ratio x01.0 0.1%  
Sales to assets ratio x1.00.2 566.6%   
Return on assets %11.26.8 164.7%  
Return on equity %16.88.4 199.5%  
Return on capital %25.512.0 213.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m52815,001 3.5%   
Fx outflow Rs m7,1935,150 139.7%   
Net fx Rs m-6,6659,851 -67.7%   
CASH FLOW
From Operations Rs m2,360-100,393 -2.4%  
From Investments Rs m3,008-24,202 -12.4%  
From Financial Activity Rs m-5,108135,705 -3.8%  
Net Cashflow Rs m26011,110 2.3%  

Share Holding

Indian Promoters % 0.0 52.9 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 4.0 255.0%  
FIIs % 23.8 26.6 89.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 16.5 93.3%  
Shareholders   102,036 93,274 109.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   NOVARTIS  ASTRAZENECA PHARMA  DISHMAN PHARMA  CIPLA  NATCO PHARMA  

Compare GSK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty at Record Close Yet Again; IT & Realty Stocks Rally(Closing)

Indian share markets extended rally in the final hour of the trade, hitting fresh record highs while the Bank nifty touched 27,000 level for the first time. At the closing bell.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Jan 22, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - ALEMBIC PHARMA COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS